Eli Lilly has acquired Prevail, a biotech focusing on gene therapies for neurodegenerative diseases including Parkinson's, in a deal potentially worth more than $1 billion. The big US pharma is to ...
Prevail said the FDA has granted Fast Track designation for its lead gene therapy, PR001 for treatment of Parkinson’s disease patients with a GBA1 mutation (PD-GBA).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback